Anadys Pharmaceuticals

About:

Anadys Pharmaceuticals develops novel therapeutics for the treatment of chronic hepatitis C viral infections.

Website: http://www.anadyspharma.com/

Top Investors: Venrock, HBM Partners, Coastview Capital, Lotus BioScience Ventures

Description:

Anadys Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections. The company focuses on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 or TLR7. Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. As of November 22, 2011, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

Total Funding Amount:

$71.3M

Headquarters Location:

San Diego, California, United States

Founded Date:

1992-01-01

Founders:

Stelios Papadopoulos

Number of Employees:

1-10

Last Funding Date:

2005-08-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai